Active Annexin V (ANXA5) Homo sapiens (Human) Active protein

ANX5; ENX2; PP4; PAP-I; CBP-I; Anchorin CII; Calphobindin I; Endonexin II; Lipocortin V; Placental anticoagulant protein 4; Thromboplastin inhibitor; Vascular anticoagulant-alpha

Add to Cart Distributors
Overview
Properties
  • Buffer FormulationPBS, pH7.4, containing 5% Trehalose.
  • Traits Freeze-dried powder, Purity > 95%
  • Isoelectric Point4.7
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Active Annexin V (ANXA5) Packages (Simulation)
  • Active Annexin V (ANXA5) Packages (Simulation)
  • APA259Hu61.jpg Figure. SDS-PAGE
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Activity test

Annexin V (ANXA5) is a multifunctional protein that is highly expressed on the apical surfaces of syncytiotrophoblasts, and plays an important role in haemostatic regulations, maintaining blood fluidity of the placenta. Lower ANXA5 levels have been observed in M2/ANXA5 haplotype carrying chorion. The association found between the maternal carriage of the M2/ANXA5 haplotype and an elevated risk of IUGR and/or PE supports the hypothesis that carrier status of this haplotype and the consequently reduced placental ANXA5 expression might be responsible, at least partially, for the onset of these gestational vascular complications. Annexin V is a calcium-dependent phospholipid binding protein that can be used to bind Phosphatidylserine (PS) during an early apoptosis event where the PS becomes exposed at the cell surface. Jurkat cells were treated with 10 uM camptothecin for 4h, 2*105 cells which were resuspended in binding buffer were stained with 5 ug recombinant human Annexin V-FITC and 10 ul Propidium iodide (PI) for 20min in dark room temperature. The flow cytometry was used to detect the early apoptotic and late apoptotic of camptothecin-treated Jurkat cells (Figure 1), the combination of Annexin V-FITC and propidium iodide allows for the distinction between early apoptotic cells (Annexin V-FITC positive and propidium iodide negative), late apoptotic and/or necrotic cells (Annexin V-FITC and propidium iodide positive), and viable cells (unstained). Thus, the recombinant human Annexin V-FITC can bind Phosphatidylserine (PS) at early apoptosis of Jurkat.

Usage

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

Storage

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Citations

  • Markers of apoptotic dysfunctions in schizophreniaPubmed: 24466757
  • Involvement of Anomalous Apoptosis in Impairments to Synaptic Plasticity in Post-Traumatic Stress DisorderSpringer: Source
  • Collectins, C3 complement protein, annexin V and C-reactive protein in acute ischemic stroke: interrelation and implication to upregulated apoptosis and inflammationSmartscitech: Source
  • Annexin A5 Protein as a Potential Biomarker for the Diagnosis of AsthmaPubmed: 30182154

Recommend products